Valneva SE VALN
Annual
Quarterly
No annual revenue total was found in Valneva SE's SEC filings.
Valneva SE (VALN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
173.54M
+6.8% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VALN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Saint-Herblain, France
- SEC filer status
- Accelerated filer
- SEC CIK
- 1836564
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Dec 31, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Dec 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 14, 2026 | Dec 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 22, 2026 | Dec 31, 2026 |
| 6-K | Current report (foreign issuer) | Jun 25, 2026 | Dec 31, 2026 |
All 268 Valneva SE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.